- Lobbying
- Lobbying by Purdue Pharma L.P.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Alfred Mottur | Sr Communications Counsel Senate Commerce Comm; Communications Counsel Senate Commerce Comm; Law Clerk Federal District Court Bangor, ME; Communications Counsel-Sen. Commerce Com; Law Clerk-Federal District Court-Bangor, ME |
Nadeam Elshami | CoS, Dem. Ldr Pelosi; Comms.Dir/Sr. Adv., Dem.Ldr Nancy Pelosi; Dep. Comms. Dir/Sr. Adv., Speaker Pelosi; Sr. Comms. Adv./Dep. Comms. Dir/Spokesman/Natl Press Sec, Sen Durbin; Dep. CoS/Comms Dir/Press Sec, Rep Schakowsky; Dep Press Sec, Sen Boxer |
Laura Johnson | Legislative intern - Senate HELP Committee |
Jerome Murray | Chief of Staff, Rep. Stacey Plaskett; Legislative Director, Rep. G.K. Butterfield; Associate Director, Democratic Steering and Outreach Committee, Sen. Harry Reid; Legislative Director, Rep. Chaka Fattah; Staff Assistant, Rep. Chaka Fattah |
Marc Lampkin | Policy Dir Senate Republican Conf Sectys office, General Counsel House Republican Conference, Staff/Counsel House Education and Labor Comm |
William Moschella | PrincAssocDepAG DOJ,AsstAG DOJ,ChfLegCouns/Parliam Hs Judic Comm,ChfInvestigativeCouns Hs Judic Comm,GC Hs Rules Comm,Couns Hs Judic Comm,Couns/Parliam Hs Gov Rel Comm,SrLegAsst Rep Frank Wolf,LegAsst RepFrank Wolf,ComputerSysManager Rep Frank Wolf |
Emily Felder | n/a |
Brian Burns | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Monitoring legislative and regulatory activities impacting the pharmaceutical industry.
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate